Preclinical studies have supported the use of CDK4/6 inhibitors in the treatment of HER2-positive breast cancers, this strategy being particularly promising in HER2+ER+ tumors for the presence of a crosstalk between signaling-linked to HER2 and ER. Here, ERBB2 is linked to breast carcinoma.